ABUS
Arbutus BiopharmaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Positive readouts/cost reductions or a value-accretive partnership/financing at favorable terms could re-rate shares toward higher analyst highs and specialist takeover/partner interest, supporting the bull target.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.8.
What can break
Clinical/program delays or negative data
Momentum
49
Value
41
Sentiment
65
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.68 · Bull $7.35 · Bear $3.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-26 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $5.50
Why
Momentum49 · Δ7d -20.0
Value41 · Δ7d -0.1
Sentiment65 · Δ7d +1.8
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
49
26% active weight
Current posture
7d trendSoftening
Δ7d
-20.0
Δ21d
+7.0
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
65
34% active weight
Current posture
7d trendImproving
Δ7d
+1.8
Δ21d
-1.4
Why this grade
Composite grade C. Momentum 49.3 / Value 41.1 / Sentiment 64.6
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$900.77M
Beta
0.72
Shares Out
197.54M
P/E (TTM) · Derived
-26.1
P/S (TTM)
62.02
P/FCF (TTM) · Derived
-22.01
Rev YoY
+10054.5%
EPS YoY
-776.0%
Gross Margin
+100.0%
Op Margin
-320.4%
Net Debt
-$87.28M
Current Ratio
54.26
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology